Presenile dementia
Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial
Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development
Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature
Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Accelerating Alzheimer’s Research: The Alzheimer’s Drug Discovery Foundation
Alzheimer’s disease, drug discovery, research funding, venture philanthropy, cognitive aging, dementia treatments
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment
Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment